Repatha: New Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes

Repatha is a California-based pharmaceutical company that discovers and develops autoinjectors and prefilled single-dose syringes for the treatment of hyperlipidemia.